Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Recessive inheritance means a child is affected only when they inherit two copies of the same gene variant, one from each parent, which is why healthy carrier parents can still have an affected child. When both partners carry the same variant, each pregnancy typically carries a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of inheriting neither copy, though risks shift with shared ancestry, family history, and the specific condition involved. Carrier screening, genetic counseling, and reproductive options such as IVF with preimplantation testing are all worth weighing, and several important details are explained below.
Because inherited risk often shows up first as subtle symptoms in a parent, sibling, or child, it helps to get clarity on any current health concerns before making long-term family plans. Take a free, instant, online symptom check to better understand what may be going on and to see which next steps, tests, or specialists make the most sense for you.
Last reviewed for medical accuracy: 08/18/2026
When couples consider starting or expanding their family, understanding genetic risks is an important step. One common pattern of inheritance is autosomal recessive, where both parents carry one copy of a mutated gene but typically do not show symptoms themselves. Hypophosphatasia (HPP) is one example of an autosomal recessive condition. In families with a history of HPP, each pregnancy carries specific risks—most notably a 25 percent sibling risk of having an affected child.
Autosomal recessive traits require two copies of a mutated gene—one from each parent—to cause the condition. Key points include:
For families concerned about autosomal recessive HPP 25 percent sibling risk, this means that if one child has HPP, each subsequent child has a 1-in-4 chance of being affected, regardless of previous siblings’ outcomes.
Hypophosphatasia is a rare genetic disorder affecting bone mineralization and the development of teeth. It results from mutations in the ALPL gene, which impairs an enzyme called alkaline phosphatase. The severity ranges from mild (adult form) to life-threatening (perinatal form). Common features can include:
While symptoms vary, knowing your risk allows you to plan and access early interventions if needed.
Review Your Family History
Discuss any known cases of HPP or related bone disorders among relatives. Even distant history may hint at carrier status.
Consider Carrier Screening
Genetic testing for both partners can confirm whether you carry a mutation in the ALPL gene. Many labs offer panels that include HPP along with other autosomal recessive conditions.
Understand the 25 Percent Sibling Risk
If you already have one child with HPP, remember each new pregnancy carries:
Once you know your carrier status, you can explore several paths:
Each option has medical, emotional, and financial considerations. Discussing them with a genetic counselor can help you weigh pros and cons.
Facing a 25 percent sibling risk for an autosomal recessive condition like HPP may feel overwhelming. To stay grounded:
If prenatal testing indicates an affected fetus, your medical team will:
For children born without HPP but at risk for carrier-related issues (e.g., mild bone pain), routine pediatric follow-up can catch emerging concerns early.
If you or a family member notices symptoms such as unexplained bone pain, frequent fractures, or early tooth loss, don’t hesitate. You can start with a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide if you need to see a specialist.
Always speak to a doctor about any symptom that’s severe, sudden, or persistent—especially if it could be life-threatening or seriously affect quality of life.
Understanding these facts empowers you to make informed choices without undue fear. Genetic conditions can feel daunting, but knowledge and planning offer the best path forward.
Please remember: this information is educational and not a substitute for professional medical advice. Always speak to a doctor or genetic counselor about any serious concerns or decisions affecting your health or family.
(References)
* Pietrzyk JJ. [Genetic counseling]. Pediatr Pol. 1976 Apr;51(4):455-61. PMID: 772579.
* Wilson MG. Genetic counseling. Curr Probl Pediatr. 1975 May;5(7):1-51. doi: 10.1016/s0045-9380(75)80019-3. PMID: 1093815.
* Emery AE. Genetic counselling. Br Med J. 1975 Jul 26;3(5977):219-21. doi: 10.1136/bmj.3.5977.219. PMID: 1148739; PMCID: PMC1674115.
* Elit L. Familial ovarian cancer. Can Fam Physician. 2001 Apr;47:778-84. PMID: 11340759; PMCID: PMC2018423.
* Knisely AS, Mieli-Vergani G, Whitington PF. Neonatal hemochromatosis. Gastroenterol Clin North Am. 2003 Sep;32(3):877-89, vi-vii. doi: 10.1016/s0889-8553(03)00050-5. PMID: 14562579.
* Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007 Apr 10;25(11):1329-33. doi: 10.1200/JCO.2006.09.1066. PMID: 17416853; PMCID: PMC2267287.
* Almaani N, Liu L, Dopping-Hepenstal PJ, Lai-Cheong JE, Wong A, Nanda A, Moss C, Martinéz AE, Mellerio JE, McGrath JA. Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa. Acta Derm Venereol. 2011 May;91(3):262-6. doi: 10.2340/00015555-1053. PMID: 21448560.
* Jayadev S, Bird TD. Hereditary ataxias: overview. Genet Med. 2013 Sep;15(9):673-83. doi: 10.1038/gim.2013.28. Epub 2013 Mar 28. PMID: 23538602.
* Kruszka P, Martinez AF, Muenke M. Molecular testing in holoprosencephaly. Am J Med Genet C Semin Med Genet. 2018 Jun;178(2):187-193. doi: 10.1002/ajmg.c.31617. Epub 2018 May 17. PMID: 29771000; PMCID: PMC6125165.
* Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, CGC, Karlan BY, Khan S, Klein C, Kohlmann W, CGC, Kurian AW, Laronga C, Litton JK, Mak JS, LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, CGC, Senter-Jamieson L, CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001. Epub 2021 Jan 6. PMID: 33406487.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.